AACR-NCI-EORTC International Conference

CALL FOR ABSTRACTS
AACR-NCI-EORTC
INTERNATIONAL CONFERENCE
MOLECULAR TARGETS AND
CANCER THERAPEUTICS
DISCOVERY, BIOLOGY, AND CLINICAL APPLICATIONS
THE PREMIER INTERNATIONAL MEETING
FEATURING NOVEL CANCER THERAPEUTICS
November 5-9, 2015
John B. Hynes Veterans Memorial Convention Center | Boston, MA
Abstract Submission Deadline: Tuesday, August 4 • Late-Breaking Abstract Submission Deadline: Thursday, September 24
Early Registration Deadline: Monday, August 24 • Advance Registration Deadline: Monday, October 5
Continuing Medical Education ActivityAMA PRA Category 1 Credits™ available
www.AACR.org
AACR-NCI-EORTC
INTERNATIONAL CONFERENCE
MOLECULAR TARGETS AND
CANCER THERAPEUTICS
DISCOVERY, BIOLOGY, AND CLINICAL APPLICATIONS
THE PREMIER INTERNATIONAL MEETING
FEATURING NOVEL CANCER THERAPEUTICS
November 5-9, 2015
John B. Hynes Veterans Memorial Convention Center • Boston, MA
Abstract Submission Deadline: Tuesday, August 4
Late-Breaking Abstract Submission Deadline: Thursday, September 24
Early Registration Deadline: Monday, August 24
Advance Registration Deadline: Monday, October 5
ABOUT THE COVER
1
2
3
4
1. Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs on tumor
cells. Mol Cancer Ther. January 2015:14;129.
2. The morphology of SW480 colorectal cancer cells in response to the treatment
with TGFβ for 48 hours have migrated through 8 μm-diameter pores in a
Transwell assay. Clin Cancer Res. November 15, 2014:20;5835.
3. The predicted binding model in which tivantinib (ARQ197) binds to the
colchicine binding site of tubulin, calculated by GOLD docking program.
Mol Cancer Ther. December 2014:13;2978.
4. 2-day-old zebrafish embryo showing developing lymphatic vessels in green
(lyve1:egfp) and endothelial cell nuclei in red (kdrl:nls:mcherry). Mol Cancer
Ther. October 2014:13;2450.
TABLE OF CONTENTS
Organizing and Scientific Committees........................................................................................................................................................ 2
Program Schedule.............................................................................................................................................................................................4
Abstract Submission Categories and Guidelines................................................................................................................................... 10
Late-Breaking Abstract Submission Guidelines......................................................................................................................................12
Accommodations and Travel.........................................................................................................................................................................14
Continuing Medical Education......................................................................................................................................................................16
Financial Support for Attendance...............................................................................................................................................................17
Registration........................................................................................................................................................................................................18
General Information....................................................................................................................................................................................... 20
Press....................................................................................................................................................................................................................22
Support Opportunities...................................................................................................................................................................................24
Exhibit Information.........................................................................................................................................................................................25
Webcasts of Sessions.....................................................................................................................................................................................26
Registration Form............................................................................................................................................................................................27
ABOUT THE CONFERENCE ORGANIZERS
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s oldest and largest
professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer.
AACR membership includes more than 35,000 laboratory, translational, and clinical researchers; population
scientists; other health care professionals; and cancer advocates residing in 101 countries. The AACR marshals
the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology,
diagnosis, and treatment of cancer by annually convening more than 25 conferences and educational workshops, the largest of
which is the AACR Annual Meeting with over 19,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific
journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well
as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert
peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the
potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of
cancer research and related biomedical science in saving lives from cancer.
The National Cancer Institute (NCI), founded in 1937, is the U.S. Federal Government’s principal agency for
cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports
research, training, health information dissemination, and other programs with respect to the cause, diagnosis,
prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and
the families of cancer patients.
The European Organization for Research and Treatment of Cancer (EORTC), based in Brussels, Belgium, unites
European cancer clinical research experts from all disciplines for trans-national collaboration. It links a network
of over 2,500 collaborators from all disciplines involved in cancer treatment and research in more than 300
hospitals in over 30 countries and offers an integrated approach to drug development, drug evaluation
programs, and medical practices.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
1
ORGANIZING AND SCIENTIFIC COMMITTEES
ORGANIZING COMMITTEE CO-CHAIRPERSONS:
Carlos L. Arteaga, MD
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA (AACR)*
James H. Doroshow, MD
National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)*
Roger Stupp, MD
University Hospital Zürich (USZ), Zürich, Switzerland (EORTC)*
SCIENTIFIC COMMITTEE CO-CHAIRPERSONS:
Levi A. Garraway, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA (AACR)*
Lee J. Helman, MD
National Cancer Institute, Bethesda, MD, USA (NCI)*
Jean-Charles Soria, MD, PhD
Institut Gustave-Roussy, Villejuif, France (EORTC)*
SCIENTIFIC COMMITTEE:
Cory Abate-Shen, PhD, Columbia University Irving Comprehensive Cancer Center, New York, NY, USA (AACR)
Jeffrey S. Abrams, MD, National Cancer Institute-DCTD, Rockville, MD, USA (NCI)
Scott A. Armstrong, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA (AACR)
Anna D. Barker, PhD, Arizona State University, Scottsdale, AZ, USA (AACR)
John C. Byrd, MD, The Ohio State University, Columbus, OH, USA (AACR)*
Phillippe Cassier, MD, Centre Léon Bérard, Lyon, France (EORTC)
Jenny C. Chang, MD, Houston Methodist Hospital, Houston, TX, USA (AACR)
Rajesh Chopra, MBBS, PhD, Celgene Corporation, Summit, NJ, USA (EORTC)
Karen M. Cichowski, PhD, Brigham & Women’s Hospital, Boston, MA, USA (AACR)
Jerry M. Collins, PhD, National Cancer Institute-DCTD, Rockville, MD, USA (NCI)
Barbara A. Conley, MD, National Cancer Institute-DCTD, Rockville, MD, USA (NCI)
William L. Dahut, MD, National Cancer Institute, Bethesda, MD, USA (NCI)
Filippo de Braud, MD, Istituto Nazionale dei Tumori, Milan, Italy (EORTC)
James H. Doroshow, MD, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
2
MOLECULAR TARGETS AND CANCER THERAPEUTICS
Lori S. Friedman, PhD, Genentech, Inc., South San Francisco, CA, USA (AACR)
James L. Gulley, MD, PhD, National Cancer Institute, Bethesda, MD, USA (NCI)*
Toby Tucker Hecht, PhD, National Cancer Institute, Rockville, MD, USA (NCI)
Lee J. Helman, MD, National Cancer Institute, Bethesda, MD, USA (NCI)
Manuel Hidalgo, MD, PhD, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain (EORTC)
Patrick Hwu, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (AACR)
Antoine Italiano, MD, Institut Bergonié, Bordeaux, France (EORTC)*
S. Percy Ivy, MD, National Cancer Institute-DCTD, Rockville, MD, USA (NCI)
Paula M. Jacobs, PhD, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
Ulrik Lassen, PhD, Rigshospitalet, Copenhagen, Denmark (EORTC)
Jose A. Lopez-Martin, MD, “12 de Octubre” University Hospital, Madrid, Spain (EORTC)
Patricia M. LoRusso, DO, Yale Cancer Center, New Haven, CT, USA (AACR)
Christophe Massard, MD, Institut Gustave-Roussy, Villejuif, France (EORTC)
Paul S. Meltzer, MD, PhD, National Cancer Institute, Bethesda, MD, USA (AACR)
Franziska Michor, PhD, Dana-Farber Cancer Institute, Boston, MA, USA (AACR)
Gordon B. Mills, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (AACR)
Stephen A. Munk, PhD, Ash Stevens Inc., Detroit, MI, USA (AACR)
Ruth Plummer, MA, DPhil, BMBCh, MD, FRCP, Newcastle University, Newcastle Upon Tyne, United Kingdom (EORTC)
Yves G. Pommier, MD, PhD, National Cancer Institute-CCR, Bethesda, MD, USA (NCI)
Eric Raymond, MD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (EORTC)
Victoria M. Richon, PhD, Sanofi Oncology, Cambridge, MA, USA (AACR)
Jordi Rodon, MD, Vall d’Hebron University Hospital, Barcelona, Spain (EORTC)
Joel P. Schneider, PhD, National Cancer Institute, Frederick, MD, USA (NCI)
Geoffrey I. Shapiro, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA (AACR)
David B. Solit, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA (AACR)
Jeffrey A. Sosman, MD, Vanderbilt University Medical Center, Nashville, TN, USA (AACR)
Patricia S. Steeg, PhD, National Cancer Institute, Bethesda, MD, USA (NCI)
Beverly A. Teicher, PhD, National Cancer Institute, Bethesda, MD, USA (NCI)
Craig B. Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA (AACR)
Joseph E. Tomaszewski, PhD, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
Christopher J. Twelves, MD, St. James Institute of Oncology, West Yorkshire, United Kingdom (EORTC)
Victor E. Velculescu, MD, PhD, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA (AACR)
Emile E. Voest, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands (EORTC)
Roger Von Moos, DMD, Kantonsspital Graubünden, Chur, Switzerland (EORTC)
Thomas E. Yankeelov, PhD, Vanderbilt University Medical Center, Nashville, TN, USA (AACR)
Timothy A. Yap, MD, Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom (EORTC)
Antoine Yver, MD, MSc, AstraZeneca, Gaithersburg, MD, USA (AACR)
James A. Zwiebel, MD, National Cancer Institute, Rockville, MD, USA (NCI)*
*member of Executive Committee
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
3
PROGRAM SCHEDULE*
(*Subject to change. Visit www.AACR.org/Targets15 for an updated program schedule.)
THURSDAY, NOVEMBER 5, 2015
Registration
10:00 a.m.-6:30 p.m.
Educational Session 1: Immunotherapy 101
3:00 p.m.-4:30 p.m.
Session Co-Chairpersons: Jolanda de Vries, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands, and Mary L.
(Nora) Disis, University of Washington, Seattle, WA, USA
Title to be announced
Jolanda de Vries
Title to be announced
Stephen Gottschalk, Baylor College of Medicine, Houston, TX, USA
Immune checkpoint inhibitors: Opportunities and challenges
Mary L. (Nora) Disis
Additional speaker to be announced
Educational Session 2: Mutation Profiling / Return of Genetic Data
4:45 p.m.-6:15 p.m.
Session Co-Chairpersons: Lee J. Helman, National Cancer Institute, Bethesda, MD, USA, and Sharon E. Plon, Baylor College of
Medicine, Houston, TX, USA
Title to be announced
Lee J. Helman
National scale cancer sequencing and treatment response data integration in the Netherlands
Edwin Cuppen, University Medical Center Utrecht, Utrecht, The Netherlands
Returning germline results to cancer patients
Sharon E. Plon
Opening Networking Reception
6:30 p.m.-8:00 p.m.
FRIDAY, NOVEMBER 6, 2015
Registration
6:30 a.m.-5:30 p.m.
Continental Breakfast
7:00 a.m.-8:00 a.m.
Welcome and Opening Remarks
8:00 a.m.-8:05 a.m.
¢ Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA (AACR)
¢ Lee J. Helman, National Cancer Institute, Bethesda, MD, USA (NCI)
¢ Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France (EORTC)
4
MOLECULAR TARGETS AND CANCER THERAPEUTICS
Keynote Lectures
8:05 a.m.-9:35 a.m.
Updates on engineered T cells as cancer therapies
Carl H. June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
Impact of gut microbiota in cancer development and therapeutics
Laurence Zitvogel, Institut Gustave-Roussy, Villejuif, France
Break
9:35 a.m.-10:00 a.m.
Plenary Session 1: Cellular Immunotherapy
10:00 a.m.-12:00 p.m.
Session Co-Chairpersons: Alexander M.M. Eggermont, Institut Gustave-Roussy, Villejuif, France, and Crystal L. Mackall,
National Cancer Institute, Bethesda, MD, USA
Title to be announced
Crystal L. Mackall
Additional speakers to be announced
Exhibit Show
12:00 p.m.-4:00 p.m.
Poster Session A
12:15 p.m.-3:15 p.m.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
5
PROGRAM SCHEDULE*
(*Subject to change. Visit www.AACR.org/Targets15 for an updated program schedule.)
Concurrent Sessions 1-4
3:30 p.m.-5:30 p.m.
Concurrent Session 1: Radiomics: Imaging in the Context of Drug Development and Personalized Medicine
Session Co-Chairpersons: E.G. Elisabeth de Vries, University Medical Center Groningen, Groningen, The Netherlands, and
Robert J. Gillies, Moffitt Cancer Center & Research Institute, Tampa, FL, USA
The radiology reading room of the future
Robert J. Gillies
Incorporating molecular imaging methods in early drug development
E.G. Elisabeth de Vries
Radiogenomics
Hugo Aerts, Brigham & Women’s Hospital, Boston, MA, USA
Concurrent Session 2: Liquid Biopsies to Monitor Clonal Evolution and Drug Resistance
Session Co-Chairpersons: Alberto Bardelli, IRCC - University of Turin Medical School, Candiolo, Italy, and Luis A. Diaz,
Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
Analysis of circulating tumor DNA to monitor clonal evolution
Muhammed Murtaza, Translational Genomics Research Institute, Phoenix, AZ, USA
Comprehensive detection of structural alterations in the circulation of cancer patients
Mark Sausen, Personal Genome Diagnostics, Baltimore, MD, USA
Heterogeneity, drug resistance, and clonal dynamics in colorectal cancers
Alberto Bardelli
Concurrent Session 3: Handling Toxicities of Immune Checkpoints/Checkpoint Blockade
Session Co-Chairperson: Antoine Italiano, Institut Bergonié, Bordeaux, France
Toxicities from CTLA-4 and PD1 immune checkpoint inhibition: An overview
Antoine Italiano
Additional speakers to be announced
Concurrent Session 4: Therapeutic Vaccines
Session Co-Chairpersons: James L. Gulley, National Cancer Institute, Bethesda, MD, USA, and Daniel E. Speiser, Ludwig Cancer
Research Center/University of Lausanne, Laussane, Switzerland
Introduction
James L. Gulley
Targeting epithelial-mesenchymal transition via brachyury-based cancer vaccines
Claudia M. Palena, National Cancer Institute-CCR, Bethesda, MD, USA
Developing personalized neoantigen-based cancer vaccines
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA, USA
DNA vaccines as treatment for prostate cancer
Douglas G. McNeel, University of Wisconsin-Madison, Madison, WI, USA
Closing remarks
Daniel E. Speiser
SATURDAY, NOVEMBER 7, 2015
Registration
7:00 a.m.-5:30 p.m.
Continental Breakfast
7:00 a.m.-8:00 a.m.
Plenary Session 2: Immunotherapy Checkpoints
8:00 a.m.-10:00 a.m.
Session Co-Chairperson: Paola A. Ascierto, Istituto Nazionale Tumori, Naples, Italy
Title to be announced
Paola A. Ascierto
Additional speakers to be announced
6
MOLECULAR TARGETS AND CANCER THERAPEUTICS
Break
10:00 a.m.-10:20 a.m.
Plenary Session 3: Update on Targeting RAS and Cancer
10:20 a.m.-12:20 p.m.
Session Co-Chairpersons: Mariano Barbacid, Spanish National Cancer Research Center, Madrid, Spain, and Frank McCormick,
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
Targeting the MAPK cascade in K-RAS driven cancer
Mariano Barbacid
Nontraditional chemical approaches to directly target K-RAS
Kevan M. Shokat, University of California/Howard Hughes Medical Institute, San Francisco, CA, USA
KRAS dependency in pancreatic cancer
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
Targeting K-RAS stemness
Frank McCormick
Poster Session B
12:30 p.m.-3:30 p.m.
Exhibit Show
12:30 p.m.-4:00 p.m.
Concurrent Sessions 5-8
3:45 p.m.-5:45 p.m.
Concurrent Session 5: Systems Biology
Session Co-Chairpersons: Trey Ideker, University of California, San Diego, CA, USA, and Walter Kolch, Systems Biology Ireland,
Dublin, Ireland
The Cancer Cell Map Initiative: Mapping molecular networks for tumor stratification and treatment
Trey Ideker
From the cancer landscape to personalized treatment
Lodewyk F. Wessels, Netherlands Cancer Institute, Amsterdam, The Netherlands
Personalized cancer diagnostics and therapeutics based on the computational modeling of signal transduction networks
Walter Kolch
Concurrent Session 6: Advances in Targeting the Hormone Axis
Session Co-Chairpersons: Johann S. de Bono, Institute of Cancer Research, Sutton, United Kingdom, and Peter S. Nelson,
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Resistance mechanisms subverting the AR program in CRPC: Opportunities for new therapeutics
Peter S. Nelson
Title to be announced
Johann S. de Bono
Additional speaker to be announced
Concurrent Session 7: Analysis of Single Cells
Session Co-Chairpersons: Caroline Dive, CRUK Manchester Institute, Manchester, United Kingdom, and Daniel A. Haber,
Massachusetts General Hospital, Charlestown, MA, USA
Using CTCs to improve outcomes in SCLC: Single cell profiling, ex vivo cultures, and mouse models
Caroline Dive
Fluid biopsy in prostate cancer, from biochemical relapse to castrate resistance
Peter Kuhn, University of Southern California, Los Angeles, CA, USA
Microfluidic isolation and molecular analysis of single CTCs
Daniel A. Haber
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
7
PROGRAM SCHEDULE*
(*Subject to change. Visit www.AACR.org/Targets15 for an updated program schedule.)
Concurrent Session 8: Cancer Epigenetics and Metabolism
Session Co-Chairpersons: Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, and Roger Stupp,
University Hospital Zürich, Zürich, Switzerland
Epigenetic therapies for TET/IDH-mutant leukemias
Ross L. Levine
Additional speakers to be announced
SUNDAY, NOVEMBER 8, 2015
Registration
7:00 a.m.-5:30 p.m.
Continental Breakfast
7:00 a.m.-8:00 a.m.
Plenary Session 4: Advances in Targeted Therapy
8:00 a.m.-10:00 a.m.
Session Co-Chairpersons: José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY, USA, and Josep Tabernero,
Vall d’Hebron University Hospital, Barcelona, Spain
Speakers to be announced
Break
10:00 a.m.-10:20 a.m.
Plenary Session 5: Advances in Targeted DNA Repair
10:20 a.m.-12:20 p.m.
Session Co-Chairpersons: Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA, USA, and Jean-Charles Soria,
Institut Gustave-Roussy, Villejuif, France
ERCC1 alternative read outs
Jean-Charles Soria
POLQ and PARP inhibitor
Alan D. D’Andrea
Exploiting oncogene-induced DNA damage as a vulnerability to treat cancer: ATR inhibitors
Oscar Fernandez-Capetillo, Spanish National Cancer Research Center, Madrid, Spain
PARP trapping versus PARP catalytic inhibition and coupling with TDP1
Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD, USA
Poster Session C
12:30 p.m.-3:30 p.m.
Exhibit Show
12:30 p.m.-4:00 p.m.
8
MOLECULAR TARGETS AND CANCER THERAPEUTICS
Plenary Session 6: Resistance to Targeted Therapy
3:45 p.m.-5:45 p.m.
Session Co-Chairpersons: Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA, and Richard M. Marais, Cancer Research
UK Manchester Institute, Manchester, United Kingdom
Title to be announced
Levi A. Garraway
Mechanisms of resistance of targeted therapies in leukemia
John C. Byrd, The Ohio State University Wexner Medical Center, Columbus, OH, USA
Title to be announced
Richard M. Marais
Additional speaker to be announced
MONDAY, NOVEMBER 9, 2015
Registration
7:00 a.m.-12:00 p.m.
Continental Breakfast
7:00 a.m.-8:00 a.m.
Plenary Session 7: Tumor Microenvironment
8:00 a.m.-10:00 a.m.
Session Co-Chairpersons: Marina Y. Konopleva, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, and
Christophe Massard, Institut Gustave-Roussy, Villejuif, France
Altered metabolism in leukemic microenvironment
Marina Y. Konopleva
The multifaceted role of Notch signaling in tumor/microenvironment interaction
Jon C. Aster, Brigham & Women’s Hospital/Harvard Medical School, Boston, MA, USA
Notch inhibitors in clinic
Christophe Massard
Additional speaker to be announced
Break
10:00 a.m.-10:20 a.m.
Plenary Session 8: The In Vitro Patient
10:20 a.m.-12:20 p.m.
Session Co-Chairpersons: James H. Doroshow, National Cancer Institute-DCTD, Bethesda, MD, USA, and Emile E. Voest,
Netherlands Cancer Institute, Amsterdam, The Netherlands
Use of tumor organoids in personalized medicine
Emile E. Voest
Title to be announced
James H. Doroshow
Ovarian PDX models: Of mice and (wo)men...and personalized treatment
Paul Halvska, Merck Research Laboratories, Rahway, NJ, USA
High-throughput drug screens in cancer cell models to enable precision cancer medicine
Matthew Garnett, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
Closing Remarks/Adjourn
12:20 p.m.-12:30 p.m.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
9
ABSTRACT SUBMISSION CATEGORIES AND GUIDELINES
When submitting an abstract for the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference using the
Online Abstract Submission System, authors will be asked to choose the appropriate category below that best describes the
scientific content of the abstract. This information will be used as a guide by the members of the Scientific Committee in their
review of abstracts. Before making a selection, authors should review the entire list for the most appropriate abstract category.
Angiogenesis and antiangiogenesis agents
Immune response to therapies
Animal models
In vitro and in vivo models for targets
Apoptosis, necrosis, and autophagy
MAPK pathways
Bioinformatics
Metabolism
Biomarkers
Metastasis and invasion
Cancer stem cells
Molecular classification of tumors
Cell cycle regulators
Monoclonal antibodies
Cellular responses to therapy
mTOR/PI3-Kinase
Chemistry
Natural products
Chemoprevention
New molecular targets
Clinical trials
Novel assay technology
Differentiation
Pediatric early drug development
DNA repair and modulation
Pharmacogenetics, pharmacogenomics, and
therapeutic response
Drug delivery
Drug design
Drug metabolism, transport, and biodistribution
Drug resistance and modifiers
Drug screening
EGFR/Her2
Epigenetic regulation of tumor immunity
Epigenetic targets
Gene therapies
Genomics, proteomics, and target discovery
Heat shock proteins
Hormonal agents and therapy
Imaging
Immune checkpoints
Immune mechanisms invoked by radiation therapy
Immune modulators
Pharmacokinetics and pharmacodynamics
Protein-protein interaction
Radiotherapeutics
RNA and RNA-based technologies and therapies
Signal transduction modulators
Target identification and validation
Therapeutic agents: Biological
Therapeutic agents: Small molecule kinase inhibitors
Therapeutic agents: Other
Topoisomerase inhibitors
Toxicology
Tubulin-interacting agents
Tumor immunology targets
Tumor microenvironment
Tumor suppressors
Immune monitoring/clinical correlates
10
MOLECULAR TARGETS AND CANCER THERAPEUTICS
Guidelines for Preparation and Submission of Abstracts
(Submission deadline: 11:59 p.m. U.S. Eastern Time, Tuesday, August 4, 2015)
Authors must submit abstracts for presentation at the 2015 AACR-NCI-EORTC
Molecular Targets and Cancer Therapeutics conference using the AACR
Online Abstract Submission System, which will be available at www.AACR.
org/Targets15 beginning Monday, June 15, 2015. You can create, modify, and
submit abstracts until the Tuesday, August 4, 2015, submission deadline.
Complete instructions on the use of the AACR Online Abstract Submission
System will be provided online.
While the online abstract submitter has been optimized for the current
versions of most browsers, Safari version 3.2 or higher is recommended
for Mac users and Microsoft Internet Explorer version 8.0 or higher is
recommended for Windows users. Users of IE 8.0 or 9.0 must display the
online submitter in Compatibility View. (From the Command Bar, select
Tools, and then select the “Compatibility View settings” option. Enter
abstractsonline.com into the window, click the “Add” button, and then click
the “Close” button.)
Browsers should be set to enable JavaScript and to accept cookies. Users who
need assistance in properly updating and configuring their browsers should
contact Abstract Submission Customer Service at 217-398-1792 or support@
abstractsonline.com.
Content of Abstracts
Authors who submit abstracts confirm that they have not previously published
these data, that they have not previously presented them at a large national
annual scientific meeting, and that they are not planning to present or publish
them prior to the dates of the 2015 AACR-NCI-EORTC Molecular Targets and
Cancer Therapeutics conference.
Each abstract should contain: (a) an introductory sentence indicating the
purposes of the study; (b) a brief description of pertinent experimental
procedures; (c) a summary of the new, unpublished data; and (d) a statement
of the conclusions.
Authors must accept sole responsibility for the statements in their abstracts.
Abstracts should be carefully proofread to avoid errors in the published
literature. American spelling should be used throughout the abstract. For
more information regarding American spelling, please refer to Scientific
Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth
Edition (Council of Science Editors, 2014).
NEW IN 2015!
Late-Breaking Abstract
Submission
Abstracts that contain new data
(unavailable at the time of the
August 4 regular submission
deadline) may be submitted as a
late-breaking abstract beginning
on Tuesday, September 15, 2015.
Submissions must be completed
by Thursday, September 24, 2015.
Late-breaking abstracts will be
considered for both oral and poster
presentations.
Expanded Opportunities for
Short Talks
A subcommittee of the Scientific
Committee will evaluate highly rated
regular and late-breaking abstracts
and where thematically appropriate,
invite authors to present a short
talk in one of the eight Concurrent
Sessions in the program. All accepted
abstracts are eligible. Not all sessions
will include short talks.
Release Date for Abstracts
All accepted abstracts are
scheduled to be posted online via
the conference itinerary planner on
Monday, October 26, 2015 (with
the exception of those abstracts
selected for inclusion in the AACR
press program). Abstracts will not be
available before this date.
Copyright Transfer/Abstract Presentation
On behalf of all authors, the corresponding author must:
1.
Transfer copyright of the abstract to the AACR for publication
2.Confirm that an author will register to attend the 2015 AACR-NCIEORTC Molecular Targets and Cancer Therapeutics conference and
present the abstract.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
11
ABSTRACT SUBMISSION CATEGORIES AND GUIDELINES
Abstract Control Number
An abstract control number (e.g., 15-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all
email correspondence regarding the abstract. Please refer to the abstract control number in any abstract communications.
Financial Relationships of Co-Authors
Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract
authors. You will be asked to disclose your financial relationships and the financial relationships of all of your co-authors. For more
information on financial relationships, visit www.AACR.org/CME.
Length of Abstracts
The combined length of the abstract body, title, and tables may not exceed 3,000 characters, not including spaces and the author
string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.
Disclosure of Chemical Structures
At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific
work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol)
organic or inorganic molecules, peptides, or proteins/nucleic acids co-crystallized with low-molecular-weight molecules.
If chemical compounds were used, the submitting author is further required to indicate whether the complete chemical structures
of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required
to be included at the time of abstract submission; rather, indication of the intent to disclose any such structures at the time of
presentation is required.
The Scientific Committee will evaluate the information provided by the submitting author and determine the acceptability of
the abstract for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for
participation; however, a limited number of these abstracts may be accepted for presentation if deemed to be of sufficient
scientific merit.
Submission Deadline
The deadline for abstract submissions is 11:59 p.m. U.S. Eastern Time, Tuesday, August 4, 2015. Abstracts submitted in any
form after the deadline will not be considered by the Scientific Committee. No changes may be made in abstracts after the
August 4, 2015, deadline.
Guidelines for Preparation and Submission of Late-Breaking Abstracts
(Submitter opens: Tuesday, September 15, 2015. Submission deadline: 11:59 p.m. U.S. Eastern Time, Thursday, September 24, 2015)
Late-Breaking Abstract Submission Process
Abstracts detailing highly significant and timely findings in any area of molecular targets and cancer therapeutics that were
not available at the time of the regular abstract deadline will be considered for both oral and poster presentation at the
2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference. Only those abstracts that are deemed
to be of high scientific priority will be accepted. All stakeholders, including members of industry, are encouraged to submit
late-breaking abstracts.
Late-breaking abstract submission will open on Tuesday, September 15, 2015 and close at 11:59 p.m. U.S. Eastern Time on
Thursday, September 24, 2015. Late-breaking abstracts must be submitted using the AACR Online Abstract Submission System,
which will be available at www.AACR.org/Targets15 over these dates only.
A special subcommittee of the Scientific Committee will evaluate the merit of late-breaking abstracts.
12
MOLECULAR TARGETS AND CANCER THERAPEUTICS
Deadline for Withdrawal of Abstracts
The AACR cannot comply with any request for withdrawal of an abstract that will delay the publication of the Program. However,
requests to withdraw abstracts will be accepted through Friday, September 19, 2015. Withdrawal requests must be sent by email
to abstract@aacr.org. Withdrawal requests must include the abstract control number and title as well as an explanation of the
reason for withdrawal.
Presentation of Abstracts at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Every abstract that has been accepted for publication in the online Proceedings must also be presented at the meeting.
Specifically, the author listed as the presenter for an abstract submission must register for the meeting and attend the session
in which the abstract is scheduled to discuss in detail the research outlined in the published abstract, according to the specific
guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to
present the abstract, he or she must contact the AACR Program Development Department to designate a co-author to serve
as the presenter. If no authors are available to present the abstract, the presenter must withdraw the abstract immediately by
contacting the AACR Program Development Department at 215-440-9300 or abstract@aacr.org.
Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:
¢
The withdrawal of the abstract from the session
¢
The removal of the abstract from the online Proceedings
¢
The loss of future abstract submission/authorship privileges for the presenter of the abstract
Abstract Release and Publication
With the exception of those abstracts selected for inclusion in the AACR press program, all accepted abstracts are scheduled
to be posted online via the conference itinerary planner on Monday, October 26, 2015. Abstracts will not be released earlier than
that date. After the conference, the presented abstracts will be published as an online-only supplement to the AACR journal
Molecular Cancer Therapeutics.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
13
ACCOMMODATIONS AND TRAVEL
The conference will be held at the John B. Hynes Veterans Memorial Convention Center, located in the heart of Boston’s historic
Back Bay neighborhood and just 5 miles/8 km from Boston’s Logan International Airport. In many ways, the Hynes Convention
Center is a city within a city - connected to two major retail complexes that contain just about everything you need during your
stay. Fast food, fine dining, sundries, personal services, world-class shopping - all under one roof. Attendees at the 2015 Molecular
Targets and Cancer Therapeutics conference can experience a serious slice of Boston without ever worrying about the weather.
The AACR has contracted with several hotels to offer reduced room rates for attendees at this year’s conference. The Sheraton
Boston Hotel will serve as the headquarter hotel for the 2015 Molecular Targets and Cancer Therapeutics conference, with the
Hilton Boston Back Bay and Marriott Copley Place also serving as official conference hotels. Please review the pricing options
below and the map on page 15 before making reservations.
Hotel reservations can be made by phone or online through AACR Housing. AACR Housing will open Monday, June 22, 2015 and
accept reservations through Monday, October 5, 2015. After October 5, reservations and rates will be subject to hotel availability.
Room reservations must be guaranteed with a major credit card. To make a reservation please visit the Accommodations and
Travel webpage at www.AACR.org/Targets15.
r
p
Ma
e
mb
Nu
t
ol
ter
Po
rne
en
e
r
r
C
t
e
n
l
oo
nt
er
ess
dI
d
ts
ub
Ce
utd
ree
ak
ee
itn
ua
F
s
O
Do
M
F
p
ran
s
Q
/
/
r
e
S
u
/
e
e
e
e
k
o
t
l
a
e
n
e
h
o
o
g
si
si
rs
st
ff
pl
Sin
Tri
Sm
Bu
Co
Hig
On
Ind
Re
Ba
ate
eR
s
tel
Ho
te
Ra
l
te
Ho
1 Sheraton Boston $249/ $289/ Yes
Yes
Yes
$9.95 No
Indoor
1
1
(Headquarter hotel)
$249 $329
(in guest Charge
rooms)
m
o
Ro
S
p.
m
Co
a
Bre
No
ng
i
ark
lf P
Se
24
No
No
hours
2 Hilton Boston Back Bay $243/ $263/ Yes
Yes
Yes
No
No
Indoor
1
1 6:30 a.m.-
$243 $283
Charge Charge
12:00 a.m.
(in guest
Mon-Thurs
rooms)
7:00 a.m.
12:00 a.m.
Fri-Sat
st
kfa
ce
i
erv
$51
$43
No
3 Marriott Copley Place $245/ $265/ Yes
Yes
Yes
No
No
Indoor
2
2 24
No
No
$245$285 Charge Charge hours
(in guest
rooms)
$53
Room rates are in U.S. Dollars.
For more information on the convention center and conference hotels, please visit www.AACR.org/Targets15 and follow the link
for Accommodations and Travel.
14
ing
rk
Pa
la et
V
MOLECULAR TARGETS AND CANCER THERAPEUTICS
Travel to Boston
The closest major airport to the Hynes
Convention Center and conference
hotels is Boston’s Logan International
Airport (BOS), located approximately
5 miles / 8 km (15-20 minutes) from the
Hynes Convention Center.
The AACR has named Gant Travel
Management as its official travel
coordinator for this conference. Gant will
provide custom itineraries with the lowest
applicable airfares and best journey
time. Fly on United Airlines, the official
airline of this conference, and save with
special discounts exclusive to attendees
and guests. Full mileage credit will be
earned by frequent flyer club members.
To receive the exclusive discounts, please
contact Gant toll-free at 877-924-2298
(630-227-3818 if outside of the
U.S./Canada) or by email at
aacr@ganttravel.com.
Gant is open from 7:30 a.m. to 6:00 p.m.
U.S. Central Time, Monday through Friday.
Amtrak train service is also readily
available for attendees traveling from the
Eastern U.S. to Boston. Amtrak’s Back Bay
Station is approximately one mile from
the Hynes Convention Center.
For additional information on travel to
Boston and ground transportation once
you arrive, please visit www.AACR.
org/Targets15 and follow the link for
Accommodations and Travel.
International Travel
Researchers from more than 50 different countries around the world regularly participate in this joint AACR-NCI-EORTC
conference. If you plan to attend the 2015 Molecular Targets and Cancer Therapeutics conference, please contact the American
Consulate in your country to review the current regulations for travel to the United States. Obtaining the proper documentation
may take several weeks or months, depending on your location, so please contact the consulate as soon as possible if you are
considering attending this conference. Information is also available on the U.S. Department of State website at
www.travel.state.gov.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
15
CONTINUING MEDICAL EDUCATION (CME)
The AACR’s Continuing Medical
Education (CME) Program brings the
latest cancer research from “bench
to bedside and back.” The AACR
has been awarded Full Accreditation
status from the Accreditation Council
for Continuing Medical Education
(ACCME). The CME Program consists
of educational interventions designed
to encourage the analysis and
discussion of the latest findings in
all areas of basic, translational, and
clinical cancer research not only
among researchers, but also by
engaging clinicians in this scientific
discourse. The AACR is committed
to advance the ability of clinicians
to apply critical aspects of cancer
research to the clinical practice of
oncology to aid in the detection,
diagnosis, treatment, and prevention
of cancer.
Continuing Medical Education ActivityAMA PRA Category 1 Credits™ will
be available. Details will be available
online at www.AACR.org/Targets15.
16
MOLECULAR TARGETS AND CANCER THERAPEUTICS
FINANCIAL SUPPORT FOR ATTENDANCE
AACR Scholar-in-Training Awards
AACR Associate members in good standing who submit abstracts may be considered for a Scholar-in-Training Award to offset
a portion of the registration, travel, and subsistence expenses incurred in attending this conference. The number of awards
provided and the dollar amounts of each award will be based on available funding. The award application deadline is
Tuesday, August 4, 2015. Additional information, abstract submission, and application instructions are available online at
www.AACR.org/Targets15.
AACR Minority-Serving Institution (MSI) Faculty Scholar in Cancer Research Awards
The AACR offers awards in cancer research for participation in its meetings and conferences to full-time faculty of
Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American
Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other postsecondary institutions as defined by the U.S.
Department of Education) who are scientists at the Assistant Professor level or above. The AACR MSI Faculty Scholar Awards
program is supported by a generous grant from the Center to Reduce Cancer Health Disparities of the National Cancer Institute.
The purposes of the awards are to increase the scientific knowledge base of faculty members at MSIs, to encourage them in their
research, and to assist in inspiring their students to pursue careers in cancer research. The award application deadline is Tuesday,
August 4, 2015. Additional information and application instructions are available online at www.AACR.org/Targets15.
AACR Minority Scholar in Cancer Research Awards
The AACR is pleased to administer this important award program that is supported by a generous grant from the Center to
Reduce Cancer Health Disparities of the National Cancer Institute (NCI) and provides funds for the participation of meritorious
minority scientists in AACR meetings and conferences. These awards are intended to enhance the education and training of
minority researchers and to increase the visibility and recognition of minorities involved in cancer research. Eligible scientists
are full-time predoctoral (graduate or medical) students or residents, clinical or postdoctoral fellows, and junior faculty who are
either engaged in cancer research or who have the training and potential to make contributions to this field. This program applies
only to racial/ethnic minority groups that have been identified by the NCI as being traditionally underrepresented in cancer and
biomedical research. These groups are African American/Black, Alaska Native, Hispanic American, Native American, and Native
Pacific Islander. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may
receive one of these awards. The award application deadline is Tuesday, August 4, 2015. Additional information and application
instructions are available online at www.AACR.org/Targets15.
AACR Women in Cancer Research Scholar Awards
Women in Cancer Research (WICR) Scholar Awards are awarded to AACR-WICR members in good standing who are scientistsin-training and presenters of meritorious scientific papers at this year’s conference. AACR-WICR members in good standing who
are graduate and medical students, residents, and postdoctoral and clinical fellows who submit abstracts are eligible to apply for
this award which provides funding to offset a portion of the registration, travel, and subsistence expenses incurred in attending
this conference. The award application deadline is Tuesday, August 4, 2015. Additional information, abstract submission, and
application instructions are available online at www.AACR.org/Targets15.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
17
REGISTRATION
Individuals wishing to attend the conference can register online beginning in early July at www.AACR.org/Targets15 or by
returning the registration form on page 27 of this brochure. Attendee registration includes admission to all scientific sessions,
poster sessions, the networking reception on November 5, conference continental breakfasts on November 6, 7, 8, and 9, and
coffee breaks. All registrants agree to follow the Code of Conduct, Policies, and Procedures for the conference outlined on page 21
of this brochure.
Registration will not be processed without full payment. Government or other payment orders are not accepted. All payments
must be in U.S. currency, drawn on a U.S. bank. Visa, MasterCard, and American Express are also accepted for payment. Places at
the conference are on a first-come, first-served basis, according to the date of registration.
Registration Rates
Please note the two options for registering below: Premium (which includes access to Webcasted sessions) and Standard (which
does not include access to Webcasted sessions).
Conference registrants will receive one complimentary drink ticket to the Networking Reception. Onsite registration will be
available at the Hynes Convention Center beginning on Thursday, November 5. All registrations are for the full conference.
Spouse registration is not available in advance and may only be purchased onsite. All spouse registrations must be tied to an
existing attendee record and is not available to individuals working in the cancer research field. Spouse fee includes only meals
and social activities provided during the conference and does NOT admit individuals to lecture sessions. The fee for spouse
registration is $175.
Premium Package
Standard Package
(Includes full individual access to the 2015 AACR-NCI-EORTC
Molecular Targets and Cancer Therapeutics Webcast)
(Does not include Webcast access)
Advance
Early
August 25-Regular/Onsite
Until August 24October 5After October 5
Advance
Early
August 25-Regular/Onsite
Until August 24October 5After October 5
AACR and EORTC Members
Active/Affiliate (Nonprofit)
$ 784$ 989$1,004
Active/Affiliate (Industry)$ 994$1,124$1,274
Associate
$ 544$ 694$ 714
Patient Advocate
$ 274$ 299$ 324
AACR and EORTC Members
Active/Affiliate (Nonprofit)
$ 685$ 890$ 905
Active/Affiliate (Industry)$ 895$1,025$1,175
Associate
$ 445$ 595$ 615
Patient Advocate
$ 175$ 200$ 225
Nonmembers
Nonprofit
$1,024$1,224$1,264
Industry
$1,324$1,554$1,624
Pre-/Postdoctoral Student1
$ 674$ 774$ 829
Patient Advocate2
$ 374$ 399$ 424
Nonmembers
Nonprofit
$ 875$1,075$1,115
Industry
$1,125$1,355$1,425
Pre-/Postdoctoral Student1
$ 525$ 625$ 680
Patient Advocate2
$ 225$ 250$ 275
Students registering onsite must show a valid student ID. Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they
are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.
1
Patient advocates registering for this conference must submit a biography or a curriculum vitae and the advocate verification form to the AACR Survivor and Patient
Advocacy Department at advocacy@aacr.org for verification.
2
18
MOLECULAR TARGETS AND CANCER THERAPEUTICS
Refund Policy
Requests for refunds must be made in writing and received by Friday, October 2, 2015. Refund requests may be sent by email to
molecular@compusystems.com. There will be a $100 administrative fee for processing cancellations received by October 2. After
October 2, no refunds can be made.
Survivor and Patient Advocate Opportunities
The AACR strongly encourages the involvement of survivors and patient advocates in this conference and is pleased to offer
discounted registration rates to this group. Advocates must submit a biography or a curriculum vitae and the advocate verification
form to receive the discounted rate. You can find the advocate verification form online at www.AACR.org/SurvivorsAndAdvocates.
Please contact Karen Russell Mills at advocacy@aacr.org or 215-446-7104 for further information. Onsite registration at this special
rate will not be available.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
19
GENERAL INFORMATION
AACR Membership
AACR membership is available to individuals who are interested in joining the AACR and registering for this conference at
discounted member rates. AACR membership offers an array of benefits, some of which include: reduced subscription rates
to AACR’s eight scientific journals; abstract sponsorship privileges for AACR Annual Meetings; and networking and scientific
exchange with leading researchers. The AACR is also eager to support the exchange of knowledge and research with investigators
who are located in countries with emerging economies. Significantly reduced membership dues are available for these
investigators.
Eligibility for Registration at AACR and EORTC Member Rates
Nonmember individuals interested in joining the AACR and registering at the early registration rate must submit membership
applications no later than August 17, 2015. Individuals who are interested in joining the AACR and registering at the advance
registration member rate must submit membership applications no later than September 28, 2015. Only individuals who are listed
on the membership rolls as members in good standing as of October 30, 2015, will be accorded the privilege of registering for
the conference at the member rates noted on the registration form. If, upon review of the membership application, a candidate is
deemed ineligible for the membership category to which he or she has applied, then the candidate will need to register in advance
at the nonmember rate. Membership information and the Membership Application form can be downloaded from the AACR
website at www.AACR.org/Membership. Contact the Membership Department at 215-440-9300 or membership@aacr.org with
any questions.
Assistance for Attendees with Disabilities
This AACR-NCI-EORTC conference is accessible to all registrants. Attendees with special requirements for transportation, hotel
accommodations, or other facilities associated with the conference should notify the AACR in advance when registering or by
emailing meetings@aacr.org.
Location
The conference will be held at the John B. Hynes Veterans Memorial Convention Center (the Hynes Convention Center), located in
Boston’s Back Bay area. The Center is conveniently located close to public transportation for easy access by Boston’s “T” subway
system and commuter rails. In many ways, the Hynes Convention Center is a city within a city. The Hynes is connected to not one,
but two major retail complexes—Prudential Center and Copley Place—that contain just about everything attendees need during
the conference. Fast food, fine dining, sundries, personal services, and world-class shopping - all under one roof. Attendees can
experience Boston without ever worrying about the weather! Enter the Prudential Center through the Hynes South Lobby. Turn
right for the Sheraton Boston Hotel, Starbucks, dining, and business center. A left turn leads to the Prudential Center, home to an
extensive food court and fine dining, as well as boutiques and shops including Saks Fifth Avenue and Lord & Taylor.
Boston attractions provide more compelling things to see and do than any other convention city in North America. From
America’s history found along the Freedom Trail to world-famous museums and international cuisine. The Theater District, located
only minutes from the Hynes Center, hosts Broadway plays and musicals. Jazz clubs, dance clubs, comedy clubs, and improv
theaters add to the entertainment scene. And for those who consider shopping to be the ultimate entertainment, Boston offers
the boutiques of Newbury Street and the shops at Quincy Market.
Career Mentoring Session
Sponsored by Women in Cancer Research (WICR)
Date and time to be announced
This session has been designed for graduate students, medical students and residents, and clinical and postdoctoral fellows.
Following a keynote address, attendees will meet, network, and learn from many of the leading senior scientists in cancer
research. Topics include careers in industry, writing a CV, careers in translational research, mentoring and supervising, and many
20
MOLECULAR TARGETS AND CANCER THERAPEUTICS
more. Although all conference attendees are invited to attend this session, it is geared toward early-career female investigators.
Only conference registrants may participate in this session. Onsite registration will be available on a first-come, first-served basis.
Seating is limited. Contact wicr@aacr.org with any questions and to learn more about Women in Cancer Research (WICR).
Code of Conduct, Policies, and Procedures
The AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference brings together an estimated 3,000 academics,
scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target
selection, and the impact of new discoveries in molecular biology. In order for all participants to have the opportunity to gain
the most benefit from this conference, the AACR is committed to providing a safe and secure environment. Please review the
following Code of Conduct, Policies, and Procedures for Conference Participants. By registering for the 2015 AACR-NCI-EORTC
Molecular Targets and Cancer Therapeutics conference, you agree to the following terms:
¢
The AACR prohibits intimidating, threatening, or harassing conduct of any kind during this program. This applies to all
participants – attendees, presenters, exhibitors, staff, vendors, etc.
¢
The AACR is committed to a safe, hospitable, and productive environment for all participants of this program, regardless of age,
disability, ethnicity, gender, religion, or sexual orientation.
¢
The AACR expects all participants to communicate professionally and constructively, handling dissent and disagreement with
courtesy, dignity, and an open mind, being respectful when providing feedback and being open to alternate points of view.
¢
Children under 12 years of age are not permitted in any scientific session, poster session, the exhibit hall, or any official event
taking place at this program at any time. Children cannot be left unattended or unsupervised in the convention center.
¢
Cell phones and other electronic devices must be turned off or placed on “silent” mode before entering a session. Participants
should step out of session rooms to make calls or send emails or texts as the back lighting on electronic devices is distracting to
other participants.
¢
Use of photographic or other recording or transmission devices is strictly prohibited in all sessions (lecture and poster) without
the express permission of the presenter. This is disruptive to other attendees and discourteous to speakers, who may be
presenting unpublished data.
¢
The AACR encourages the use of social media before, during, and after this program. Please remember that the use of
photographic, recording, and/or transmission devices is strictly prohibited without the express permission of the presenter.
¢
The AACR expects participants to share information about this program responsibly and clearly distinguish individual opinion
from fact.
¢
A professional photographer and videographer will be on site to document conference events and activities between November
3 and November 10, 2015. Photographs and video footage are the sole property of AACR. By registering for and attending these
events, attendees understand that AACR may use their likenesses for future promotional purposes. If you do not wish to be
photographed, please notify the photographer and/or videographer on site.
¢
Participants must obey all applicable laws and regulations of the relevant government authorities while attending this program.
Participants must comply with all applicable safety guidelines related to the conference venue.
¢
If a session room becomes too crowded, the AACR asks you to follow instructions provided by the AACR staff, Convention
Center staff, or security. Instructions may include not standing against the walls, not blocking the aisles or doors, or being
denied entry if the room becomes too crowded. The AACR and all participants are obligated to abide by the guidelines
established by the Fire Marshal in the Convention Center. If a room reaches full capacity and there is not full cooperation, the
Fire Marshall has the authority to delay or terminate the conference.
¢
The AACR, Levy Catering, Boston Sheraton Hotel, and the Hynes Convention Center encourage responsible drinking for those
drinking alcohol. Beer and wine will be offered at some official events throughout this program. Alcohol will not be served to
anyone under the age of 21. Alcoholic beverages are allowed in specific areas and must not be taken out of these areas.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
21
PRESS
22
MOLECULAR TARGETS AND CANCER THERAPEUTICS
Members of the national and international media depend on the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
conference to provide the most up-to-date information on drug development in oncology. At this year’s conference, the
American Association for Cancer Research (AACR) Communications and Public Relations Department will be conducting a press
program and staffing a press room. Reporters and PIOs from medical centers who are interested in registering for the conference
should contact Lauren Riley at lauren.riley@aacr.org. The AACR does not release media lists, but will make available companysponsored press releases on abstract presentations in the press room. For more information on the Molecular Targets and Cancer
Therapeutics press program contact Jeff Molter at 267-210-3965 or jeff.molter@aacr.org, Julia Gunther at 215-446-6896 or
julia.gunther@aacr.org, or Lauren Riley at 215-446-7155 or lauren.riley@aacr.org.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
23
SUPPORT OPPORTUNITIES
Demonstrate Your Support of Life-Saving Cancer Research
Conference Support
The AACR Foundation welcomes support from individuals,
foundations, corporations, and other organizations
interested in bringing this important international
education program to an estimated
3,000 conference participants from across the U.S. and
the world. Our conference supporters enjoy recognition
in the Molecular Targets and Cancer Therapeutics
program, as well acknowledgement on the AACR website
promoting the conference. Additionally, the AACR
Foundation acknowledges your generous support in
onsite signage throughout the conference venue. At the
conference, you will enjoy interacting face to face with
cancer research professionals—academics, scientists,
and pharmaceutical industry representatives—to discuss
innovations in drug development, target selection, and
the impact of new discoveries in molecular biology.
For information about supporting this important
conference, please contact the AACR Foundation
at 215-446-7165, or:
Anizia.Karmazyn@aacr.org
Senior Director, Philanthropy and Corporate Partnerships
Jessica.Cestone@aacr.org
Director of Development
Corporate Support
Corporate supporters of the AACR-NCI-EORTC 2015
Molecular Targets and Cancer Therapeutics conference
also enjoy these sponsor benefits:
¢
Build visibility for your organization in a competitive
marketplace.
¢
Target highly influential decision makers and opinion leaders.
¢
Networking opportunities.
¢
Access to over 3,000 registrants.
¢
Complimentary scientific registrations for the conference.
¢
Opportunity to rent the pre- or post-registration list.
For information about distinct corporate support opportunities, please contact:
Iain.Mitchell@aacr.org
Assistant Director, Corporate Relations
215-446-7120
Professional Educational Grants
Continuing Medical Education (CME)
Ronald.Arthur@aacr.org
Senior Manager, Office of CME
215-440-9300, ext. 206
24
MOLECULAR TARGETS AND CANCER THERAPEUTICS
EXHIBIT INFORMATION
Opportunities are available to reserve
an exhibit space at this conference.
Over 3,000 scientists and researchers
who are leading the discovery and drug
development effort against cancer
worldwide are expected to attend
this year’s conference. Don’t miss this
opportunity to further your business by
meeting new contacts from industry,
government, and academia. AACR Annual
Meeting Exhibitors receive an additional
priority point for reserving a booth at
this conference. Booths are assigned on
a first-come, first-served basis so be sure
to get your application in before space is
sold out. For further information please
contact Lisa A. McGlashen, AACR Senior
Exhibits Manager, at 215-440-9300 or
exhibits@aacr.org.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
25
WEBCASTS OF SESSIONS
As in previous years, the AACR will make a limited number of selected session webcasts free to all interested researchers. In
addition, attendees can purchase exclusive online streaming access to the audio and slides of all scientific sessions presented at
the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference.*
¢
Presentation slides synchronized with recorded audio presentations
¢
Speakers’ mouse movements captured and included in playback
¢
Available on compatible mobile devices and smart phones such as iPad, iPod Touch, and iPhone
¢
Presentations searchable by session title, presentation title, and speaker name
¢
Exclusive access to online content for 15 months after the conference
Purchase access to the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics by
selecting the Premium Package when registering and get the lowest rates.
*Participation in the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics webcasts is left to the discretion of each speaker.
As a result, some presentations may not be available for webcast, and some webcast presentations may not include all slides. Sessions will not be streamed live. Selected
session webcasts will be made available free within 24 hours, and the remaining webcasts will be made available in late November. Attendees who purchased webcast
access will receive login information via email at that time.
26
MOLECULAR TARGETS AND CANCER THERAPEUTICS
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
REGISTRATION FORM
Register Online: www.AACR.org/Targets15
Name and Address Information
Check here if you are a member of: q AACR Membership # ____________ q EORTC q Nonmember
q Dr.
q Mr.
q Ms.
Last/Family Name
First Name/Middle Initial
Title/Position
Department/DivisionInstitution
Street/Building or Post Office Box
City/State or Province
Zip or Postal Code/Country
TelephoneFax
Email
q New address. Please change my AACR mailing information.
q If you will require special accommodations, please specify: ____________________________________________________________________________________________
_______________________________________________________________________________________________________________________________________
Nonmember Predoctoral Student/Postdoctoral or Clinical Fellow Certification
“I certify that the above named person is presently enrolled at this University and working toward a degree or fellowship in a field related to cancer research.”
Name (Registrar, Dean, or Dept. Head)
Signature (Registrar, Dean, or Dept. Head)
Title
University
Additional Registrant Information
Scientific Research Focus (check only one):
q Basic
q Translational
q Clinical
q Behavioral Science
Primary Area of Research (check only one):
q Behavioral Science
q Biochemistry and Biophysics
q Biostatistics
q Carcinogenesis
q Cellular Biology
q Chemistry
q Clinical Investigations/Clinical Population Science Trials
q Computational Biology
q Endocrinology
q Epidemiology
q Genetics and Genomics
q Immunology
q Molecular Biology
q Preclinical Pharmacology and Experimental Molecular Therapeutics
q Prevention Research
q Radiation Oncology/Radiation Biology
q Research Administration/Business Development
q Tumor Biology
q Virology
q Other ______________________________________
Institution Type (check only one):
q Academic
q Association/Professional/Organization
q Cancer Center (NCI-designated)
q Foundation/Advocacy Organization
q Government
q Prevention Research
q Hospital/Medical Center/Clinic
q Industry/Private Sector
q Nonprofit Research Organization
q Other ______________________________________
q Other Cancer Center
Race or Ethnic Background (check only one): q Caucasian q African American or Black
q Native Hawaiian or Pacific Islander q Other ______________________________
Gender:
q Male
q Hispanic or Latino
q Asian
q Native American
q Alaskan Native
q Female
Information concerning gender and ethnic background is solicited to enable the association to ensure that its programs are appropriately serving all members of the cancer research community.
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
27
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
REGISTRATION FORM
Register Online: www.AACR.org/Targets15
Premium Package
Standard Package
Advance
Early
August 25-Regular/Onsite
Until August 24October 5After October 5
Advance
Early
August 25-Regular/Onsite
Until August 24October 5After October 5
AACR and EORTC Members
Active/Affiliate (Nonprofit)
$ 784$ 989$1,004
Active/Affiliate (Industry)$ 994$1,124$1,274
Associate
$ 544$ 694$ 714
Patient Advocate
$ 274$ 299$ 324
AACR and EORTC Members
Active/Affiliate (Nonprofit)
$ 685$ 890$ 905
Active/Affiliate (Industry)$ 895$1,025$1,175
Associate
$ 445$ 595$ 615
Patient Advocate
$ 175$ 200$ 225
Nonmembers
Nonprofit
$1,024$1,224$1,264
Industry
$1,324$1,554$1,624
Pre-/Postdoctoral Student1
$ 674$ 774$ 829
Patient Advocate2
$ 374$ 399$ 424
Nonmembers
Nonprofit
$ 875$1,075$1,115
Industry
$1,125$1,355$1,425
Pre-/Postdoctoral Student1
$ 525$ 625$ 680
Patient Advocate2
$ 225$ 250$ 275
TOTAL ENCLOSED OR CHARGED US$ _________________________________
TOTAL ENCLOSED OR CHARGED US$ _________________________________
(Includes full individual access to the 2015 AACR-NCI-EORTC Molecular Targets and
Cancer Therapeutics Webcast)
(Does not include Webcast access)
Nonmember individuals interested in joining AACR and registering at the early registration rate must submit an applications no later than August 17, 2015. Those individuals interested in registering at the
advance registration rate must submit applications no later than September 28, 2015. Only individuals who are listed on the membership rolls as of October 30, 2015, will be accorded the privilege of
registering for the conference at the member rates noted on the registration form. If, upon review of the membership application, a candidate is deemed ineligible for the membership category to which
he or she has applied then the candidate will need to register at the nonmember rate. Membership information and the application form can be downloaded from the AACR website at www.AACR.org/
Membership. Contact the AACR Membership Department at 215-440-9300 or membership@aacr.org with any questions.
Refund Policy: Requests for refunds must be made in writing. There will be a $100 processing fee for cancellations until October 2, 2015. After October 2, no refunds can be given.
Financial Support for Attendance: The AACR is pleased to provide financial assistance to eligible investigators for participation in this conference, subject to availability of funding. Additional information
including award application instructions are available on the Financial Support for Attendance webpage for this conference.
Method of Payment
q Check or money order enclosed, payable to American Association for Cancer Research, drawn on a U.S. bank.
q VISA
Card # q MasterCard
q American Express
Expiration Date
Print Name of Cardholder
Signature of Cardholder
Registration fees are payable in U.S. dollars only. Personal checks are acceptable if payable through a U.S. bank.
Return to:
2015 Molecular Targets
2651 Warrenville Road
Suite 400
Downers Grove, IL 60515
Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to
cancer research.
1
Patient advocates registering for this conference must submit a biography or a curriculum vitae and the advocate verification form to the AACR Survivor and Patient Advocacy Department at advocacy@
aacr.org for verification.
2
28
MOLECULAR TARGETS AND CANCER THERAPEUTICS
2015-2016 SCIENTIFIC CONFERENCES
CRI-CIMT-EATI-AACR The Inaugural
International Cancer Immunotherapy
Conference: Translating Science into Survival
September 16-19, 2015 • New York, NY
Tumor Metastasis
Co-Chairpersons: Bruce R. Zetter,
Melody A. Swartz, and Jeffrey W. Pollard
November 30-December 3, 2015 • Austin, TX
Chromatin and Epigenetics in Cancer
Co-Chairpersons: Peter A. Jones,
Sharon Y. R. Dent, and Charles W. M. Roberts
September 24-27, 2015 • Atlanta, GA
CSHA/AACR Joint Meeting: Big Data, Computation, and
Systems Biology in Cancer
Conference Organizers: Andrea Califano, William C. Hahn,
Satoru Miyano, and Xuegong Zhang
December 1-5, 2015 • Suzhou, China
Advances in Breast Cancer Research
Co-Chairpersons: Matthew J. Ellis,
Charles M. Perou, and Jane E. Visvader
October 17-20, 2015 • Bellevue, WA
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
Co-Chairpersons: Kathleen R. Cho,
Douglas A. Levine, and Benjamin G. Neel
October 17-20, 2015 • Orlando, FL
Fourth AACR International Conference
on Frontiers in Basic Cancer Research
Chairperson: M. Celeste Simon
Co-Chairpersons: James P. Allison, John E. Dick,
Nathanael S. Gray, and Victor E. Velculescu
October 23-26, 2015 • Philadelphia, PA
The Basic Science of Sarcomas
Co-Chairpersons: Robert G. Maki, Angelo Paolo Dei Tos,
Jonathan A. Fletcher, Lee J. Helman, and Brian A. Van Tine
November 3-4, 2015 • Salt Lake City, UT
AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics
Scientific Committee Co-Chairpersons: Levi A. Garraway,
Lee J. Helman, and Jean-Charles Soria
November 5-9, 2015 • Boston, MA
Advances in Pediatric Cancer Research:
From Mechanisms and Models to Treatment and Survivorship
Co-Chairpersons: Scott A. Armstrong, Charles G. Mullighan,
Kevin M. Shannon, and Kimberly Stegmaier
November 9-12, 2015 • Fort Lauderdale, FL
New Horizons in Cancer Research:
Bringing Cancer Discoveries to Patients
Shanghai 2015
Co-Chairpersons: Lewis C. Cantley and Carlos L. Arteaga
November 12-15, 2015 • Shanghai, China
Eighth AACR Conference on the Science of
Cancer Health Disparities in Racial/Ethnic Minorities
and the Medically Underserved
Co-Chairpersons: John M. Carethers, Marcia R. Cruz-Correa,
Mary Jackson Scroggins, Edith A. Perez, Beti Thompson,
and Cheryl L. Willman
November 13-16, 2015 • Atlanta, GA
EORTC-NCI-EMA-AACR International Conference on
Innovation and Biomarkers in Cancer Drug Development
Co-Chairpersons: Denis A. Lacombe and John W. Martens
December 3-4, 2015 • Brussels, Belgium
Noncoding RNAs and Cancer
Co-Chairpersons: Howard Y. Chang,
Jeannie T. Lee, and Joshua Mendell
December 4-7, 2015 • Boston, MA
San Antonio Breast Cancer Symposium
Co-Directors: Carlos L. Arteaga, Virginia Kaklamani,
and C. Kent Osborne
December 8-12, 2015 • San Antonio, TX
AACR-IASLC Joint Conference on Lung Cancer
Chairpersons to be announced
January 4-7, 2016 • San Diego, CA
The Function of Tumor Microenvironment in
Cancer Progression
Co-Chairpersons: Raghu Kalluri, Robert A. Weinberg,
Douglas Hanahan, and Morag Park
January 7-10, 2016 • San Diego, CA
Patient-Derived Cancer Models: Present and Future
Applications from Basic Science to the Clinic
Co-Chairpersons: Manuel Hidaldo, Hans Clevers,
S. Gail Eckhardt, and Joan Seoane
February 11-14, 2016 • New Orleans, LA
10th AACR-JCA Joint Conference
Co-Chairpersons: Frank McCormick and Tetsuo Noda
February 16-20, 2016 • Maui, HI
AACR Precision Medicine Series: Cancer Cell Cycle–Tumor
Progression and Therapeutic Response
Co-Chairpersons: Julien Sage, J. Alan Diehl, and
Karen E. Knudsen
February 27-March 2, 2016 • Orlando, FL
AACR Annual Meeting 2016
Program Committee Chairperson: Scott Armstrong
April 16-20, 2016 • New Orleans, LA
Developmental Biology and Cancer
Co-Chairpersons: Hans Clevers,
Stuart Orkin, and Suzanne Baker
November 30-December 3, 2015 • Boston, MA
CALL FOR ABSTRACTS ¢ Abstract Submission Deadline: August 4, 2015
615 Chestnut Street, 17th Floor
Philadelphia, PA 19106-4404
215-440-9300 • Fax: 215-599-0111
Email: programs@aacr.org
AACR-NCI-EORTC
INTERNATIONAL CONFERENCE
MOLECULAR TARGETS AND
CANCER THERAPEUTICS
DISCOVERY, BIOLOGY, AND CLINICAL APPLICATIONS
November 5-9, 2015
John B. Hynes Veterans Memorial Convention Center • Boston, MA
Abstract Submission Deadline: Tuesday, August 4
Late-Breaking Abstract Submission Deadline: Thursday, September 24
Early Registration Deadline: Monday, August 24
Advance Registration Deadline: Monday, October 5
www.AACR.org